These results validated our design hypothesis that Beclin 1 mimetics, compounds disrupting Bcl-xL-Beclin 1 interaction, could induce autophagy and inhibit cell growth in apoptosis-deficient cancer cells. Here, BCL2L1 is linked to cancer.